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Conclusion: Our data showed that metastasis to lymph nodes
and alcohol consumption are the main factors that affect mortal-
ity in HNC patients of Tomsk region.
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Background: Risk of metastasis formation is provided by both
tumor cell biological characteristics and the microenvironment
features within the primary tumor along with local and systemic
conditions for metastatic niche formation. The inflammatory
infiltration has been shown to strongly impact on tumor progres-
sion (Whiteside, 2013). Dronca et al. (2011) showed that immuno-
suppressive factors in the tumor microenvironment may impair
not only local immune responses but also disturb systemic
immunity. Zitvogel et al. anticipate that the comprehension of
the mechanisms governing the immunogenicity of cell death will
have a profound impact on the design of anticancer therapies.To
study the impact of immune system on clinical response to
neoadjuvant chemotherapy and metastasis-free survival in
breast cancer patients.
Materials and methods: 350 patients with newly diagnosed
invasive breast cancer treated with neoadjuvant chemotherapy
(NAC) were enrolled into the study. The procedures were made
in accordance with the Helsinki Declaration. Clinical response
to chemotherapy, the 5-year metastasis-free survival and all
major clinical and morphological parameters were determined.
The original method of multidimensional data visualization was
applied to present the immune system state as integral entirety
in visual image for classification of patients with different risk
of metastasis (NovoSpark Corporation, Canada). Copy number
aberrations (CNA) of cytokine gene regions in tumor specimens
were tested using high-density microarray platform CytoScanTM
HD Array (Affymetrix, USA). Cytokine gene polymorphism was
analyzed. Subpopulations of lymphocytes and macrophages were
determined within the primary tumors by IHC.
Results: We found, that favorable clinical immediate response
to preoperative chemotherapy was related to the high levels of
IL-1beta, TNF-alpha and IL-10 production by peripheral mononu-
clear cells before the treatment. This correlation was further con-
firmed by data from the study on association between cytokine
gene functional polymorphism and response to NAC. We used
NovoSpark Corporation visualization approach allowing the
representation the immune system state as integral unit and to
discriminate breast cancer patients with high and low risk of
haematogeneic metastasis. When estimated before cancer treat-
ment, 95% of breast cancer patients had risk of metastasis. The
neoadjuvant chemotherapy and surgical tumor removal reduced
the risk of tumor progression to 62–71%. However, in a year after
adjuvant chemo- and radiotherapy, the patient group with high
risk of metastases increased to 81% again. Thus, the cancer treat-
ment can change the primarily estimated outcome prognosis in
breast cancer patients, and the monitoring of immune system
is a promising approach to predict the risk of cancer progression
or resistance to the therapy. We have found the connection
between the profile of intra-tumor inflammatory elements and
chemotherapy efficacy.Cytokine gene expression may be influ-
enced by the chromosome anomalies (CNA – Copy Number
Aberration) – deletion and amplification – of cytokine gene loci
in tumor cells. We found the close relation between the clinical
response to NAC and gain of function of IL-10 and CHI3L1
(YKL40) genes. In contrast, loss of TNF-alpha and IL-17 gene
function due to corresponding CNA was associated with good
response to NAC. Metastasis-free survival of breast cancer
patients was shown to be closely related to CNA.
Conclusion: The parameters of the activation of systemic and
intra-tumoral immune system by growing tumor and its dissem-
ination have to be validated in order to identify the new prognos-
tic markers for the efficiency of the neoadjuvant chemotherapy.
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The strong connection between cancer-related inflammation
and tumour development with pattern – recognizing receptors
(PRRs) activation results in identification of new target molecules
that could lead to improved cancer diagnosis and treatment.
TLR3, RIG1 and MDA5 synthetic ligand poly(I:C) was shown to
trigger apoptosis in cancer cells. However, TLR3 signaling also
includes NF-kB transcription factor which has emerged as
endogenous tumour promoter via stimulation of pro-
inflammatory tumour microenvironment, enhancement of
angiogenesis, tumour cell proliferation and metastasis. Thus
down regulation of NF-kB-mediated effects after TLR3 activation
is needed for implementation of TLR3 ligand-based therapy into
clinical trials.
We have earlier demonstrated that DNA and sequence specific
ODNs inhibit poly(I:C)-induced production of pro-inflammatory
cytokines in human primary fibroblasts and endothelial cells
(Cherepanova et al., Immunobiology, 2013). Using these specific
ODNs and affinity modification/isolation approach combined
with subsequent MALDI-TOF the main cellular targets for these
ODNs were identified as Ku protein – heterodimer of KU70 and
KU80 (Cherepanova et al., Exp. Opin. Biol. Ther., 2012).
The goals of this study are to reveal whether the ODNs target
poly(I:C)-induced activation in tumour cells: cervical carcinoma
(Hela) and epidermoid carcinoma (A431) and to confirm Ku
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